Recombinant human meteorin - Hoba Therapeutics
Alternative Names: HB-086; rhMeteorinLatest Information Update: 28 Jan 2025
At a glance
- Originator Hoba Therapeutics
- Class Analgesics; Non-opioid analgesics; Recombinant proteins
- Mechanism of Action Glial cell modulators; Neuron stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Peripheral neuropathies; Trigeminal neuralgia
- Research Cancer pain; Postoperative pain
- No development reported Neuropathic pain
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Neuropathic-pain in Denmark
- 22 Jan 2024 Hoba Therapeutics plans a phase Ib trial for Peripheral neuropathies (Chemotherapy-induced) (Hoba Therapeutics pipeline, January 2024)
- 11 Dec 2023 Hoba Therapeutics plans a phase I trial for Peripheral neuropathies